Johnson & Johnson's nipocalimab shows promise in Sjögren's disease trial [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
DAHLIAS is a randomised, multicentre, placebo-controlled, double-blind dose-ranging study that evaluated the effects of nipocalimab in adults with primary SjD, a chronic and debilitating autoantibody disease. This study included a Phase II dose-ranging trial for adults with moderately-to-severely active primary SjD who were seropositive for anti-Ro60 and/or anti-Ro52 IgG antibodies. It enrolled 163 adult patients aged 18–75 years and randomised into a 1:1:1 ratio to receive intravenous nipocalimab at either five or 15mg/kg or a placebo every two weeks through week 22. Additionally, all the patients received protocol-permitted standard of care. In the trial, nipocalimab was found to offer a statistically significant and clinically meaningful improvement in the ClinESSDAI score compared with placebo at 24 weeks from baseline, meeting the trial's primary endpoint. The 15mg/kg nipocalimab treatment group showed clinically meaningful improvements in secondary endpoints at week 2
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Global Hernia Mesh Devices Market Size To Worth USD 7.56 Billion By 2033 | CAGR Of 5.42% [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- TimesSquare Capital Global Health Care Q1 2024 Commentary [Seeking Alpha]Seeking Alpha
- Allergic Conjunctivitis Market Research 2024-2032 with Focus on North America [Yahoo! Finance]Yahoo! Finance
- Global Lung Cancer Surgery Market Size To Exceed USD 9.92 Billion By 2033 | CAGR Of 5.32% [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/16/24 - Beat
JNJ
Sec Filings
- 6/25/24 - Form 11-K/A
- 6/24/24 - Form 11-K
- 6/24/24 - Form 11-K
- JNJ's page on the SEC website